Skip to content
2000
Volume 3, Issue 10
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Major reasons preventing many early candidates reaching market are the inappropriate ADME (absorption, distribution, metabolism and excretion) properties and drug-induced toxicity. From a commercial perspective, it is desirable that poorly behaved compounds are removed early in the discovery phase rather than during the more costly drug development phases. As a consequence, over the past decade, ADME and toxicity (ADMET) screening studies have been incorporated earlier in the drug discovery phase. The intent of this review is to introduce the desirable attributes of a new chemical entity (NCE) to the medicinal chemist from an ADMET perspective. Fundamental concepts, key tools, reagents and experimental approaches used by the drug metabolism scientist to aid a modern project team in predicting human pharmacokinetics and assessing the “drug-like”molecule are discussed.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026033452096
2003-06-01
2025-05-09
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026033452096
Loading

  • Article Type:
    Review Article
Keyword(s): pharmacokinetics; Toxicity
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test